CMS May Take Studious Approach To Covering ESAs In Cancer Setting
Executive Summary
CMS is seeking public input on whether Medicare should respond to safety concerns about the use of erythropoiesis-stimulating agents in cancer patients by paying for ESAs only within the context of clinical studies